This open‐label 2‐period study assessed the effect of multiple‐dose administration of
rifampin, a strong cytochrome P450 3A (CYP3A) and P‐glycoprotein inducer, on the …

Purpose Sunitinib and pazopanib, two tyrosine kinase inhibitors (TKI), may be targets of
potential pharmacokinetic drug-drug interactions (P-PK-DDIs). While strong cytochrome …

Repotrectinib shows high activity against ROS1/TRK/ALK fusion-positive cancers in
preclinical studies. We explored the roles of multidrug efflux transporters ABCB1 and …

Ticagrelor is the first reversibly binding, direct-acting, oral P2Y12 receptor inhibitor. The
contribution of UDP-glucuronosyltransferases (UGTs) enzymes to the metabolism of …

Purpose Ticagrelor (AZD6140) is the first reversibly binding oral P2Y 12 receptor antagonist
in development for reduction of clinical thrombotic events in patients with acute coronary …

This analysis was conducted to assess exposure–response relationships for efficacy and
safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed …

2568 Background: Dacomitinib (D) is a highly selective irreversible small molecule inhibitor
of the HER family of tyrosine kinases in clinical development for NSCLC. Prior clinical …

Sažetak Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In
xenograft studies it inhibited tumor growth in BRAF-mutant melanoma and colorectal …

Purpose: In phase I studies with oral CI-1033, dose-limiting toxicities were primarily
gastrointestinal, supporting the exploration of iv dosing to achieve optimal drug exposures …

Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was
metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate …